BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2018 Earnings Results

Biocryst Pharmaceuticals Beats on EPS, Stock Up 3.59%

Biocryst Pharmaceuticals reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising 3.59%. The lack of revenue data and guidance indicates uncertainty about future performance. Investors may be encouraged by the company's progress in clinical trials, but the absence of specific guidance leaves some questions unanswered.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	-$0.19	N/A	+19.97%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about the company's clinical developments. They noted that while they are making progress, there are still challenges ahead.

Management highlighted progress in their clinical pipeline.

They emphasized the importance of upcoming trials for future growth.

Biocryst Pharmaceuticals Beats on EPS, Stock Up 3.59%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

Biocryst Pharmaceuticals Beats on EPS, Stock Up 3.59%

Key numbers

Management commentary